Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares Gold Trust (IAU) Price & Performance

Amylx Pharmaceuticals IncTrade
iShares Gold TrustTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs iShares Gold Trust — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while iShares Gold Trust trades at $82.91. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.

AMLXIAU
Market Cap
$2.64B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$24.19$101.57
52-Week Low
$7.82$62.49
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

iShares Gold Trust

IAU (iShares Gold Trust) trades at $82.76, up 0.3% on the day, with technical indicators showing mixed signals - a bullish moving average trend but overbought RSI levels. The ETF benefits from gold's recent momentum as inflation data aligns with expectations and geopolitical tensions boost safe-haven demand. Recent news highlights gold's strong performance with spot prices reaching $4,438/oz following July CPI data.

The outlook remains positive given gold's defensive characteristics amid economic uncertainty, though overbought technical conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy shifts and dollar strength, while institutional buying and central bank demand provide underlying support.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About iShares Gold Trust

IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.

Read more on IAU